Safety concerns grow over GLP-1 class obesity treatments; UK health authorities launch genetic analysis.

Concerns about the safety of GLP-1 class obesity treatments, including Wegovy (semaglutide), often dubbed "miracle obesity drugs" and garnering global attention, are escalating due to a series of acute pancreatitis cases. In the UK, in particular, over 400 adverse event reports, including more than 10 deaths, have prompted health authorities to investigate the situation.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England recently requested official reports of acute pancreatitis symptoms experienced by patients after taking GLP-1 class treatments such as Wegovy, Ozempic (semaglutide), Zepbound/Mounjaro (tirzepatide), and Saxenda (liraglutide). Notably, over a quarter of all reported cases this year have occurred recently, with tirzepatide-related cases accounting for nearly half.

Acute pancreatitis is a severe inflammation of the pancreas accompanied by abdominal pain, vomiting, and fever, and can be life-threatening in severe cases. The pancreas is a vital organ that secretes blood sugar-regulating hormones like insulin and glucagon, as well as digestive enzymes. When pancreatitis occurs, these functions can be severely compromised.

Currently, some studies suggest that GLP-1 compounds may increase the risk of pancreatitis. GLP-1 analogues are associated with the proliferation of pancreatic beta cells and the promotion of insulin secretion, and some opinions suggest this process could put a strain on the pancreas. However, pharmaceutical companies only list pancreatitis as an "uncommon reaction" in product information and state that these symptoms have not been directly confirmed as being caused by the treatments.

In response, experts point out that rapid weight loss can lead to gallstone formation, which may induce pancreatitis. When weight is lost rapidly, the composition of bile can change, or bile excretion may not be smooth, increasing the risk of gallstone formation. If these gallstones block the pancreatic duct, pancreatic fluid can reflux, leading to pancreatitis. Since obesity itself is a risk factor for pancreatitis, the possibility that these are phenomena occurring during obesity treatment cannot be ruled out.

Amidst this controversy, UK health authorities plan to initiate genetic analysis of patients who experienced pancreatitis symptoms after receiving GLP-1 class treatments. This aims to investigate whether specific ethnicities or genetic factors make individuals more susceptible to adverse reactions and to clarify the causal relationship between the treatments and the occurrence of pancreatitis.

As of May 13th, at least 10 reported cases to UK authorities included deaths due to pancreatitis. However, it has not yet been definitively confirmed whether the obesity drugs were the direct cause of death in all these cases.

The results of the UK health authorities' investigation are expected to further intensify the safety debate surrounding GLP-1 class treatments, once hailed as "miracle obesity drugs." For patients choosing medication for obesity treatment, a thorough understanding of their individual health status, potential side effects, and consultation with a healthcare professional are becoming even more crucial.